141 related articles for article (PubMed ID: 25706332)
1. Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program.
Baxter JD; Clark RE; Samnaliev M; Aweh G; O'Connell E
Subst Abus; 2015; 36(2):174-82. PubMed ID: 25706332
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with Medicaid patients' access to buprenorphine treatment.
Baxter JD; Clark RE; Samnaliev M; Leung GY; Hashemi L
J Subst Abuse Treat; 2011 Jul; 41(1):88-96. PubMed ID: 21459544
[TBL] [Abstract][Full Text] [Related]
3. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
[TBL] [Abstract][Full Text] [Related]
4. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine.
Clark RE; Samnaliev M; Baxter JD; Leung GY
Health Aff (Millwood); 2011 Aug; 30(8):1425-33. PubMed ID: 21821560
[TBL] [Abstract][Full Text] [Related]
5. Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States.
Lo-Ciganic WH; Donohue JM; Kim JY; Krans EE; Jones BL; Kelley D; James AE; Jarlenski MP
Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):80-89. PubMed ID: 30192041
[TBL] [Abstract][Full Text] [Related]
6. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
[TBL] [Abstract][Full Text] [Related]
7. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective.
Kinsky S; Houck PR; Mayes K; Loveland D; Daley D; Schuster JM
J Subst Abuse Treat; 2019 Sep; 104():15-21. PubMed ID: 31370980
[TBL] [Abstract][Full Text] [Related]
8. A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.
Presnall NJ; Wolf DAPS; Brown DS; Beeler-Stinn S; Grucza RA
J Subst Abuse Treat; 2019 Sep; 104():135-143. PubMed ID: 31370977
[TBL] [Abstract][Full Text] [Related]
9. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.
Clark RE; Baxter JD; Barton BA; Aweh G; O'Connell E; Fisher WH
Health Serv Res; 2014 Dec; 49(6):1964-79. PubMed ID: 25040021
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
Samples H; Williams AR; Olfson M; Crystal S
J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
[TBL] [Abstract][Full Text] [Related]
11. Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program.
Gordon AJ; Lo-Ciganic WH; Cochran G; Gellad WF; Cathers T; Kelley D; Donohue JM
J Addict Med; 2015; 9(6):470-7. PubMed ID: 26517324
[TBL] [Abstract][Full Text] [Related]
12. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
LaBelle CT; Han SC; Bergeron A; Samet JH
J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698
[TBL] [Abstract][Full Text] [Related]
13. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.
Stein BD; Dick AW; Sorbero M; Gordon AJ; Burns RM; Leslie DL; Pacula RL
Subst Abus; 2018; 39(4):419-425. PubMed ID: 29932847
[TBL] [Abstract][Full Text] [Related]
14. Differences in buprenorphine treatment quality across physician provider specialties.
Levin JS; Landis RK; Sorbero M; Dick AW; Saloner B; Stein BD
Drug Alcohol Depend; 2022 Aug; 237():109510. PubMed ID: 35753279
[TBL] [Abstract][Full Text] [Related]
15. States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.
Knudsen HK; Lofwall MR; Havens JR; Walsh SL
Drug Alcohol Depend; 2015 Dec; 157():36-43. PubMed ID: 26483356
[TBL] [Abstract][Full Text] [Related]
16. Common elements in opioid use disorder guidelines for buprenorphine prescribing.
Atkinson TJ; Pisansky AJB; Miller KL; Yong RJ
Am J Manag Care; 2019 Mar; 25(3):e88-e97. PubMed ID: 30875177
[TBL] [Abstract][Full Text] [Related]
17. A novel community-based buprenorphine program: client description and initial outcomes.
Daniels AM; Salisbury-Afshar E; Hoffberg A; Agus D; Fingerhood MI
J Addict Med; 2014; 8(1):40-6. PubMed ID: 24394496
[TBL] [Abstract][Full Text] [Related]
18. Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states.
Hammerslag L; Talbert J; Donohue JM; Sharbaugh M; Ahrens K; Allen L; Austin AE; Gordon AJ; Jarlenski M; Kim JY; Mohamoud S; Tang L; Burns M;
Drug Alcohol Depend; 2023 Sep; 250():110875. PubMed ID: 37413960
[TBL] [Abstract][Full Text] [Related]
19. National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018.
Schuler MS; Saloner B; Gordon AJ; Dick AW; Stein BD
Subst Abus; 2023 Jul; 44(3):154-163. PubMed ID: 37278310
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Medication Utilization for Opioid Use Disorder Among Medicaid-Insured HIV Patients in New York.
Choi S; Yerneni R; Healy S; Goyal M; Neighbors CJ
Am J Addict; 2020 Mar; 29(2):151-154. PubMed ID: 31951083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
